Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Invested Capital (2022 - 2025)

Oramed Pharmaceuticals' Invested Capital history spans 4 years, with the latest figure at $199.7 million for Q4 2025.

  • For Q4 2025, Invested Capital changed N/A year-over-year to $199.7 million; the TTM value through Dec 2025 reached $199.7 million, changed N/A, while the annual FY2025 figure was $199.7 million, N/A changed from the prior year.
  • Invested Capital reached $199.7 million in Q4 2025 per ORMP's latest filing, down from $202.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $223.6 million in Q3 2023 to a low of $139.9 million in Q1 2025.
  • Average Invested Capital over 4 years is $172.2 million, with a median of $155.5 million recorded in 2024.
  • Peak YoY movement for Invested Capital: surged 46.0% in 2023, then plummeted 30.44% in 2024.
  • A 4-year view of Invested Capital shows it stood at $151.2 million in 2022, then skyrocketed by 41.51% to $213.9 million in 2023, then decreased by 27.29% to $155.5 million in 2024, then rose by 28.43% to $199.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Invested Capital are $199.7 million (Q4 2025), $202.3 million (Q3 2025), and $153.6 million (Q2 2025).